{"url_path":"/sec/rkda/8-k/2026-06-15/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-270560-index.html","accession_number":"0001193125-26-270560","cik":"0001469443","ticker":"RKDA","issuer_name":"Arcadia Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-270560-index.html","primary_entity_key":"0001469443","primary_entity_name":"Arcadia Biosciences, Inc."},"word_count":142,"has_tables":true,"body_markdown":"## Item 3.02 Unregistered Sales of Equity Securities.\n\nThe disclosures in Item 1.01 of this Form 8-K are incorporated by reference into this Item 3.02 in their entirety. The Pre-Funded Warrants, Investment Options, Option Shares, Placement Agent Investment Options and Placement Agent Option Shares described in Item 1.01 above were not registered under the Securities Act of 1933, as amended (the “Securities Act”) and were offered in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder, as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws. Each investor represented, among other matters, that it was an accredited investor as defined in Regulation D promulgated under the Securities Act, and that the investor was purchasing the Securities for investment and not for resale."}